Bibliography

 

Top  Previous  Next

 

Anthropometrics

1.Devine, Ben. Gentamicin therapy. Drug Intell Clin Pharm 1974;8:650-6.
2.Hume R. Prediction of lean body mass from height and weight. J Clin Pathol.1966;19:389–91.
3.Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med 1987 Oct 22;317(17):1098 (letter)
4.DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Medicine. 1916; 17:863-71.
5.Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother. 2000 Sep;34(9):1066-9.
6.Rice, TL and Rice, KA. Commonly Used Equations for Estimating Lean Body Weight are Inaccurate. Hospital Pharmacy Volume 36, Number 9, pp 955–961
7.Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
8.Schwartz, GL.  A simple estimate of glomerular filtration rate in children  Pediatrics 1976:58:259-263.
9.Traub SL, Kichen L. Estimating ideal body mass in children. Amer J Hosp Pharm 1983;40:107-10.
10.Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: A height weight formula validated in infants, children and adults. The Journal of Pediatrics 1978 (93):1:62-66.
11.Haycock GB, et al.   Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults.  J Pediatr 1978;93:62-6.
12.Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988 Jun;84(6):1053-60.
13.Jelliffe Roger, et al. Estimation of creatinine clearance in patients with unstable renal function. Math Biosci. 14:17-24 (June) 1972.
14.Sawyer WT, et al, Variables Affecting Creatinine Clearance Prediction. Am J Hosp Pharm 1983;40:2175-80.
15.Canaday BR, et al, Fractional Adjustment of Predicted Creatinine Clearance in Females. Am J Hosp Pharm 1984;41:1842-3.
16.Chow MS, Schweizer R, Estimation of Creatinine Clearance in Patients with Unstable Serum Creatinine Concentrations: Comparison of Multiple Methods. DICP. 1985;19:385-390.
17.Rhodes PJ, et al: Evaluation of Eight Methods for Estimating Creatinine Clearance in Men. Clin Pharm. 1987;6:399-406.
18.Drusano GL, et al. Commonly used methods of estimating creatinine clearance are inadequate for elderly debilitated nursing home patients. JAGS 1988;36:437-441.
19.Lott RS, Hayton WL: Estimation of Creatinine Clearance from Serum Creatinine Concentration - a review. DICP. 1978;12:140-150.
20.Paap CM, Nahata MC. Prospective evaluation of ten methods for estimating creatinine clearance in children with varying degrees of renal dysfunction.  J Clin Pharm Ther. 1995 Apr;20(2):67-73.
21.Dionne RE, Bauer LA, Gibson GA, Griffen WO Jr, Blouin RA.  Estimating creatinine clearance in morbidity obese patients. Am J Hosp Pharm. 1981 Jun;38(6):841-4.
22.Myers GL, Miller GW, Coresh J, et al. Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program. Clinical Chemistry 2006;52(1):5-18.
23.Pierrat A, Gravier E, Saunders C, Caira MV, Ait-Djafer Z, Legras B, Mallie JP. Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and MDRD formulas. Kidney Int. 2003 Oct;64(4):1425-36.
24.Winter MA, Guhr KN, Berg, GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy 2012;32(7):604-612.

 

Aminoglycosides

1.Devine, Ben. Gentamicin therapy. DICP 1974;8:650-655.
2.Sarubbi FA, Hull JW. Gentamicin serum concentrations: pharmacokinetic predicitions. Ann Intern Med 1976;85:183-189.
3.Sawchuk RJ, Zaske DE, et al. Kinetic model for gentamicin dosing. Clin Pharmacol Ther 1977;21;3:362-369.
4.Sarubbi FA, Hull JW. Amikacin serum concentrations: predicition of levels and dosage guidelines. Ann Intern Med 1978;89:612-618.
5.Blouin RA, et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 1979;26:508-513.
6.Bauer LA, et al. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharmacy 1980;37:519-522.
7.Korsager S. Administration of gentamicin to obese patients. Int J Clin Pharmacol Ther Tox 1980;18,12:549-553.
8.Lesar TS, et al. Gentamicin dosing errors with four commonly used nomograms. JAMA 1982;248(10);1190-1193.
9.Sheiner LB, Beal S. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982 71:1344-1348.
10.Matzke GR, Burkle WS, Lucarotti RL. Gentamicin and tobramycin dosing guidelines: an evaluation. DICP 1983;17:425-432.
11.Yamaoka K, Nakagawa T, et al. A nonlinear multiple regression program based on Bayesian algorithm for microcomputers. J. Pharmacobio-Dyn., 8, 246-256 1985.
12.Burton ME, Brater DC, et al. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 37:349-357, 1985.
13.Burton ME, Chow MSS, et al. Accuracy of Bayesian and Sawchuk-Zaske dosing methods for gentamicin. Clin Pharm 1986;5:143-149.
14.Zaske DE. "Aminoglycosides", in Evans W, Schentag J, Jusko J (eds): Applied Pharmacokinetics. San Francisco. Applied Therapeutics, 1986; pp 331-381.
15.Schentag JJ, "Aminoglycosides", in Evans W, Schentag J, Jusko J (eds): Applied Pharmacokinetics. San Francisco. Applied Therapeutics, 1986; pp 382-398.
16.Fant WK. Controversies in antimicrobial therapy: Pitfalls in monitoring aminoglycoside therapy. AJHP 1986:43:641-645.
17.Chrystyn H. Validation of the use of Bayesian analysis in the optimization of gentamicin therapy. DICP 1988 22:49-53.
18.Donahue T, Yates DJ. Predictability of aminoglycoside serum levels dosed by a pharmacy protocol. Hospital Pharmacy 1988:23;11-25
19.Rodvelt KA, Zokufa H, Rotschafer JC. Aminoglycoside pharmacokinetic monitoring: An integral part of patient care? Clin Pharm 1988:7:608-613.
20.Okamoto MP, Chi A, et al. Comparison of two microcoputer Bayesian pharmacokinetic programs for predicting serum gentamicin concentrations. Clin Pharm 1990 9:708-11.
21.Tsubaki T, Chandler MHH. Evaluating new and traditional methods for aminoglycoside dosing with various degrees of renal function. Pharmacotherapy 1994; 14:330-336.

 

Vancomycin

1.Sheiner LB, Beal S. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982 71:1344-1348.
2.Matzke GR, Kovarik JM, et al. Evaluation of the vancomycin-clearance: creatinine-clearance relationship for predicting vancomycin dosage. Clin Pharm 1985;4:311-315.
3.Lake KS, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5:340-344.
4.Yamaoka K, Nakagawa T, et al. A nonlinear multiple regression program based on Bayesian algorithm for microcomputers. J. Pharmacobio-Dyn., 8, 246-256 1985.
5.Rybak MJ, Boike SC. Monitoring vancomycin therapy. DICP 1986;20:757-761.
6.Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmaco 1986;11:257-282.
7.Rybak MJ, Boike SC. Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. DICP 1986;20:64-68.
8.Cheung RP, DiPiro JT. Vancomycin: An Update. Pharmacotherapy 1986;6:153-69.
9.Matzke GR. "Vancomycin" In: Applied Pharmacokinetics, Second Edition. Spokane, WA: Applied Therapeutics, Inc., 1986. pp 399-436.
10.Musa DM, Pauly DJ. Evaluation of a new vancomycin dosing method. Pharmacotherapy 1987;7:69-72.
11.Garrelts JC, Godley PJ, et al. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin Pharm 1987;6:795-799.
12.Rodvold KA, et al. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987;6:655-658.
13.Pyrka RD, Rodvold KA, et al. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. Ther Drug Mon 1989 11:45-454.
14.Ackerman, Bruce H. Evaluation of three methods for determining initial vancomycin doses. DICP 1989;23:123-7.
15.Healy DP, et al. Vancomycin-induced histamine release and 'red man syndrome' comparison of 1- and 2-hour infusions. Antimicrobial Agents and Chemo 34; 550-554, 1990.
16.Pryka RD, Rovold KA, Erdman SM. An updated comparison of drug dosing methods part IV:vancomycin. Clin Pharmaco 1991;20:463-76.
17.Ito M, Duren L, et al. Computer program for the initiation of vancomycin therapy. Clin Farm 1993 12:126-30.
18.Leader WG, Chandler MH, and Castiglia M. Pharmacokinetic optimisation of Vancomycin therapy. Clin Pharmacokinet 28(4);327-42 1995.
19.Pou L, Rosell M, et al. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Mon 1996 18:149-153.
20.Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med. 1981 Mar;94(3):343-6.
21.Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988; 32:848–52.
22.John E. Murphy; David E. Gillespie; Carol V. Bateman. Predictability of Vancomycin Trough Concentrations Using Seven Approaches for Estimating Pharmacokinetic Parameters. Am J Health-Syst Pharm. 2006;63(23):2365-2370.
23.Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Lodise TP, Lomaestro B, Graves J, Drusano GL. Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6.
24.Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66:82–98.
25.Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6. Epub 2008 Jan 28.
26.Vandecasteele SJ and De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney International 77, 760-764 (May 2010).

 

Bayesian analysis

1.Sheiner LB, Beal S, Rosenberg B, et al: Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979;26:294.
2.Sheiner LB, Beal S. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982 71:1344-1348.
3.Schumacher GE, Barr JT. Bayesian approaches in pharmacokinetic decision making. Clin Pharm 1984 3:525-30.
4.Yamaoka K, Nakagawa T, et al. A nonlinear multiple regression program based on Bayesian algorithm for microcomputers. J. Pharmacobio-Dyn., 8, 246-256 1985.
5.Ito M, Duren L, et al. Computer program for the initiation of vancomycin therapy. Clin Pharm 1993 12:126-30.
6.Burton ME, Brater DC, et al. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 37:349-357, 1985.
7.Jelliffe R.  Effect of assumptions concerning assay error patterns upon pharmacokinetic parameter values and model behavior.  J. Vet Pharmacol Ther 17:105-109, 1994.

 

Copyright 1999-2013 by RxKinetics. All rights reserved.